secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001493152-26-002772
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Guidance, and Preferred Stock Conversion
--------------------------------------------------------------------------------

- Preliminary 2025 thyroid testing revenue of ~$34-35M, up 21% over prior year.
- Company initiates 2026 revenue guidance of ~$40M, representing 16% growth in thyroid testing.
- All outstanding Series C Preferred Stock converted into common stock at $2.02 per share, issuing ~23.3M shares.
- Company is debt-free with positive net income and EBITDA, plans to seek uplisting to Nasdaq in 2026.
- Following conversion, pro forma basic shares outstanding ~27.7M; 1315 Capital owns ~34%, Ampersand owns ~50%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315226002772/0001493152-26-002772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315226002772/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-002772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer